In a press release stating strong annual results for the cancer diagnostic producer, Biocartis also announced a change in its top management position. Its current CEO, Rudi Pauwels, has expressed his preference to focus on the longer term strategy of Biocartis, including a pathway towards a Next-Generation Sequencing based product offering. Pauwels will act as chairman of a new strategy committee of the Board. Hilde Windels, currently Deputy CEO, will assume the role of CEO until a successor is on board.
argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States.
In a press release stating strong annual results for the cancer diagnostic producer, Biocartis also announced a change in its top management position. Its current CEO, Rudi Pauwels, has expressed his preference to focus on the longer term strategy of Biocartis, including a pathway towards a Next-Generation Sequencing based product offering. Pauwels will act as chairman of a new strategy committee of the Board. Hilde Windels, currently Deputy CEO, will assume the role of CEO until a successor is on board.
argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States.